Targeted & Immunotherapy – Evidence

BREAST

Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

CSCO Breast Cancer Guideline: Updates For Hormone Receptor-positive BC in 2020

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

ESOPHAGUS

New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma

HEPATOCELLULAR CARCINOMA

Atezolizumab Plus Bevacizumab In Advanced Unresectable Or Metastatic HCC

RENAL CELL CARCINOMA 

Tivozanib In Refractory & Relapsed RCC

IMMUNOTHERAPY

Society For Immunotherapy Of Cancer (SITC) Clinical Practice Guideline On
Immune Checkpoint Inhibitor-Related Adverse Events 2021

Society For Immunotherapy Of Cancer (SITC) Consensus Definitions For Resistance
To Combinations Of immune Checkpoint Inhibitors With Targeted Therapies 2023